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Effective in vitro differentiation of adipose-derived stem cells
into Schwann-like cells with folic acid supplementation
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Shinichiro Yamada, Yu Saito, Satoru Imura, Yuji Morine, and Mitsuo Shimada
Department of Digestive and Transplant Surgery, Tokushima University, Tokushima, Japan
Abstract : Peripheral nerve injury (PNI) after pelvic surgery is a common issue with a significant impact on pa-
tients. Autologous nerve grafting is the gold standard treatment for PNI, but this technique cannot be applied 
to fine nerve fibers in the pelvis. Schwann-like cell (SLC) differentiation is a novel therapeutic strategy for this 
clinical condition. However, the efficiency of SLC differentiation remains unsatisfactory. We modified an SLC 
differentiation protocol using adipose-derived stem cells (ADSCs) and folic acid. Morphology, gene expression 
and secretion of neurotrophic factors were examined to assess the differentiation quality and phenotypic char-
acteristics. Our new modified protocol effectively induced a Schwann cell (SC) phenotype in ADSCs as assessed 
by morphology and expression of SC markers [S100 calcium-binding protein B (S100B), P < 0.01 ; p75 neurotrophic 
receptor (p75NTR), P < 0.05]. SLCs produced by the new protocol displayed a repair phenotype with decreased 
expression of ERBB2 and early growth response protein 2 (EGR2) / KROX20 (P < 0.01). Furthermore, our new pro-
tocol enhanced both mRNA expression and secretion of nerve growth factors by SLCs (P < 0.01). This protocol 
enhanced the SC characteristics and functions of ADSC-derived SLCs. This promising protocol requires further 
research and may contribute to SC-based nerve regeneration. J. Med. Invest. 68 : 347-353, August, 2021
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INTRODUCTION
 
Peripheral nerve injury (PNI) is a common issue that affects 
more than 1 million people every year worldwide and causes 
a significant degree of pain in the affected individuals (1). Au-
tologous nerve transplantation is currently the best method for 
treating PNI, but its application is limited owing to the scarcity 
of donors and the risk of neuroma formation and other compli-
cations due to a second operation (2). Moreover, PNI after pelvic 
surgery needs to be addressed to improve patients’ quality of 
life (3). Nerve transplantation is one option ; however, injured 
nerve fibers are generally fine and complex. Therefore, another 
strategy is required.
Cell transplantation is another option that has progressively 
gained popularity. Schwann cells (SCs) contribute to the removal 
of damaged myelin, secretion of nerve growth factors (NGFs) 
and the formation of new myelin. These properties are beneficial 
for the regeneration of peripheral nerves (4, 5). However, owing 
to limitations in SC separation, purification and proliferation 
technology, there is an urgent requirement for abundant alter-
native cells with lower immunogenicity. Regenerative medicine 
has recently been applied to solve these issues (6). Adipose-de-
rived stem cells (ADSCs) have been focused on because of their 
multipotency and ease of harvest. We have investigated ADSC 
multipotency and reported scientific evidence of insulin produc-
ing cells (IPCs) for clinical applications (7-11). Thus, we hypoth-
esized that ADSCs can also self-renew and differentiate into 
ectodermal lineage cells, including Schwann-like cells (SLCs). 
The most commonly used differentiation protocol for producing 
SLCs from ADSCs has been described by Kingham et al. (12). 
However, this method is still not ideal, considering the scope for 
further improvement with regard to the secretion of neurotroph-
ic factors by differentiated SLCs. Thus, it is imperative to find 
methods that will ensure the optimal performance of SLCs.
Folic acid (FA) is an inexpensive and safe substance with 
regulatory properties in various cells in the nervous system. It 
can promote chemotactic responses in glial cells, induce neuro-
trophin release and stimulate neuronal differentiation (13). FA 
can effectively promote growth, repair and recovery of damaged 
adult central nervous system (CNS) (14), provide neuroprotec-
tion and promote nerve regeneration after ischemic injury (15). 
The FA / Dihydrofolate reductase (DHFR) / AMP-activated pro-
tein kinase (AMPK)α axis improves survival and induces my-
elination of oligodendrocytes, and thus, enhances the maturity of 
oligodendrocytes in vivo and in vitro (16). FA supplementation has 
been shown to be effective in PNI treatment (17). A recent study 
on a rat PNI model has demonstrated that FA promoted prolif-
eration and migration of SCs and secretion of NGF to improve 
the repair of peripheral nerve damage (18). SCs transform into a 
repair phenotype at the site of the injured nerve to promote nerve 
regeneration (6). Then, NGFs promote autophagy of SCs through 
the p75 neurotrophin receptor (p75NTR) / AMPK / mechanistic 
target of rapamycin (mTOR) signaling pathway to accelerate 
removal and phagocytosis of myelin debris and promote the 
regeneration of axons and myelin in the early stages of PNI (19). 
The close relationship between FA and NGFs indicates they play 
a crucial role in SC-mediated nerve regeneration. However, there 
is no research on the application of FA in the differentiation pro-
cess of SLC from stem cells. And the appropriate concentration 
of FA also needs to be investigated. 
Our new modified protocol effectively induced an SC pheno-
type in ADSCs as assessed by morphology and expression of SC 
markers. Furthermore, new generated SLCs display a repair 
phenotype as decreases of Erb-B2 receptor tyrosine kinase 2 
(ERBB2) and early growth response 2 (EGR2) gene expression, 
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and show enhanced secretion capacity of NGFs. This promising 
new protocol requires further research for SC-mediated nerve 
regeneration. 
MATERIALS AND METHODS
Cell Culturing and Differentiation Protocols
Human ADSCs were purchased from Invitrogen (Grand 
Island, NY, USA) and cultured in ADSC basal medium with 
added growth supplement (Gibco, Carlsbad, CA, USA) and 
GlutaMAX-I (Gibco). Primary human SCs (ScienCell Research 
Laboratories, Carlsbad, CA, USA) were cultured in 6-well 
flat-bottom plates precoated with poly-L-lysine (2 μg / cm2, P4707, 
Sigma-Aldrich) and maintained in complete SC medium sup-
plemented with 5% fetal bovine serum (FBS), 1% SC growth 
supplement cocktail and 1% penicillin / streptomycin (ScienCell 
Research Laboratories) following the manufacturer’s instruc-
tions. To produce SCs (50 μg / ml) group, 50 μg / ml of FA was 
added into the growth medium to stimulate SCs for 3 days. 
For inducing conventional SLCs differentiation, a three-step 
protocol reported by Kingham et al. (12) was used. Briefly, 
ADSCs were seeded in collagen I-coated 6-well plates (4810-
010, IWAKI, Tokyo, Japan), cultured in α-modified Eagle’s 
medium (α-MEM, Gibco) without FBS (Gibco) and treated with 
1 mM β-mercaptoethanol (β-ME, 133-14571, Fujifilm Wako 
Pure Chemical Corporation, Osaka, Japan) for 24 h. Next, 
α-MEM with 10% FBS, 35 ng / ml all-trans-retinoic acid (ATRA, 
3027949, PeproTech Ltd., Cranbury, NJ, USA) were followed to 
treat cells for 72 h. Then, α-MEM with 10% FBS and a mixture 
of growth factors including 252 ng / ml glial growth factor-2 
(GGF-2, 90255-B, BPS Bioscience, Inc., San Diego, CA, USA), 10 
ng / ml basic fibroblast growth factor (bFGF, 100-18B, PeproTech 
Ltd.), 5 ng / ml platelet-derived growth factor (PDGF, 100-14B, 
PeproTech Ltd.) and 14 μM Forskolin (F3917, Sigma-Aldrich) 
were used to culture cells for 14 days with a medium change 
for every 3 days. For our new protocol, 50 μg / ml FA (F8758-5G, 
Sigma-Aldrich, St. Louis, MO, USA) was added as supplementa-
tion in the step 3 as the schematic representation shown in Fig. 
1. We called these SLCs as SLCs (FA). In addition, for checking 
the effects of different concertation of FA on the differentiation of 
SLCs, 10 μg / ml and 200 μg / ml FA were also used in the step 3 
of differentiation protocol and these SLCs were named as SLCs 
(FA, 10 μg / ml) and SLCs (FA, 200 μg / ml), respectively.
Morphological Analysis
Cells were seeded in a Nunc Lab-Tek II Chamber Slide Sys-
tem (154526PK, Thermo Fisher Scientific, Waltham, MA, USA) 
and stained with hematoxylin and eosin (H&E). Groups of cells 
were compared under an optical microscope.
Quantitative Real-Time Reverse Transcription Polymerase Chain 
Reaction (qRT-PCR) 
An RNeasy Mini Kit (Qiagen, Hilden, Germany) and a reverse 
transcription kit (Applied Biosystems, Thermo Fisher Scientific) 
were used to extract total RNA, which was reverse transcribed 
to obtain cDNA. qRT-PCR analyses were performed using a Ste-
pOnePlus Real-Time PCR System (Applied Biosystems, Thermo 
Fisher Scientific). The primers (TaqMan gene expression assays, 
Thermo Fisher Scientific) used were : S100B (Hs00902901_
m1), p75NTR (Hs00609976_m1), ERBB2 (Hs01001580_m1), 
EGR2 / KROX20 (Hs00166165_m1), NGF (Hs00171458_m1) 
and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
(Hs99999905_m1). Results are presented as relative mRNA 
expression normalized to GAPDH as an internal control.
Immunofluorescence Staining
Indicated cells were digested by trypsin and seeded for 
2×104 / well in a Nunc Lab-Tek II Chamber Slide System until 
adhesion. After being washed twice with PBS, 4% parafor-
maldehyde (163-20145, FUJIFILM) was used to fix the cells 
at 4°C for 30 min. Next, incubated the slides with 0.1% Triton 
X-100 (HFH10, Thermo Fisher Scientific, Inc.) for 2 min at room 
temperature for permeabilization and followed with 3% bovine 
serum albumin (BSA) diluted from MACS BSA Stock Solution 
(130-091-376, Miltenyibiotec, Bergisch Gladbach, Germany) in 
PBS for 1 h. all slides were incubated. Then, the slides were incu-
bated with an Anti-S100 beta antibody (ab52642, 1 : 100, Abcam, 
Cambridge, UK) or Anti-p75NTR (sc-271708, 1 : 50, Santa Cruz 
Biotechnology, Inc. Paso Robles, Ca, USA) at 4°C overnight. The 
next day, after being washed three times with PBS, Alexa Fluor 
488 conjugated secondary antibodies (A-11008, 1 : 500, Thermo 
Fisher Scientific, Inc.) was used to incubate slides for S100B 
and Alexa Fluor 594 conjugated secondary antibodies (A-11005, 
1 : 800, Thermo Fisher Scientific, Inc.) was for p75NTR, for 1 h at 
37°C in the dark. Then, slides were washed with PBS for three 
times protected from light and stained the nuclei by ProLong™ 
Gold Antifade Mountant with DAPI (P36931, Thermo Fisher 
Scientific, Inc.) for 10 min in the dark. A fluorescence microscope 
(BZ-X700 KEYENCE, Tokyo, Japan) was used to observe and 
photograph the slides. As for negative controls, the primary anti-
body was replaced with BSA.
Enzyme-Linked Immunosorbent Assay (ELISA)
Human NGF ELISA kits (BEK-2212-1P / 2P, Biosensis, The-
barton, Australia) were used to assess NGF secretion in the 
supernatant of different groups of cells following the manufac-
turer’s instructions. Absorbance at 450 nm was measured using 
a microplate reader and the concentration of NGF was calculated 
using a standard curve. Relative secretion capacity was normal-
ized to the cell number.
Statistical Analysis
For statistical analysis and plotting, we used Prism 7.0 soft-
ware (GraphPad, San Diego, CA, USA). Data are expressed 
as the mean ± standard deviation. Comparisons between two 
groups were evaluated using Mann-Whitney U test. Differences 
among multiple groups were tested using one way analysis of 
variance (ANOVA) followed by Tukey’s post hoc test. All exper-
iments were performed in triplicate. All P-values are two-sided 
Fig 1.　Schematic representation of the modified protocol for 
differentiating ADSCs into SLCs. adipose-derived stem cells, 
ADSCs ; Schwann-like cells, SLCs ; β-mercaptoethanol, β-ME ; all-
trans-retinoic acid, ATRA ; basic fibroblast growth factor, bFGF ; FA, 
folic acid ; glial growth factor-2, GGF-2 ; platelet-derived growth factor, 
PDGF.
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and P < 0.05 was considered significant (*P < 0.05 ;  **P < 0.01).
RESULTS
Improved protocol for generating SLCs
We searched the literature for methods to enhance differ-
entiation and function of SCs or SLCs using small molecules 
(Table 1) (13, 18, 20-26). FA was identified as a small molecule 
that may promote NGF secretion by primary SCs. Secretion of 
neurotrophic factors is a crucial function of SCs for promoting 
nerve regeneration, hence we hypothesized that FA would be an 
inexpensive, convenient and promising candidate for enhancing 
the function of SLCs. Thus, we modified our protocol by adding 
50 μg / ml FA supplementation and generated SLCs (FA) (Fig. 1).
New protocol effectively induces the SC phenotype in ADSCs
Undifferentiated ADSCs grew in clusters and displayed a 
rounded fibroblast-like shape. In contrast, SCs exhibited a clas-
sic spindle-shaped morphology with a higher aspect ratio. SLCs 
(FA) became morphologically similar to SCs after 18 days of dif-
ferentiation, exhibiting small and elongated spindle shapes with 
a bipolar or tripolar structure (Fig. 2A). 
New protocol enhances the SC characteristics of generated SLCs
The generated SLCs (FA) cultured with the new protocol 
displayed significant upregulation of the SC markers, S100B 
and p75NTR (P < 0.05 and P < 0.01, respectively, Mann-Whitney 
U test, Fig. 2B) compared with ADSCs, suggesting that the 
improved protocol effectively induced the SC phenotype in SLCs 
derived from ADSCs. Moreover, the immunofluorescence stain-
ing results showed that ADSCs had an extremely low expression 
of S100B and a moderate expression of p75NTR, while both 
high level of S100B and p75NTR were observed in SCs (Fig. 
2C). SLCs (FA) generated by new protocol showed significantly 
up-regulated levels of S100B and p75NTR, indicating that SLCs 
(FA) were similar in phenotype to SCs (Fig. 2C). Taken together, 
a large proportion of ADSCs were differentiated into SLCs (FA) 
with SC characteristics through our modified protocol.
  
SLCs produced by the new protocol display a repair phenotype
ERBB2 is a subtype of Neuregulin (NRG) receptor that can 
activate downstream signal transduction and facilitate the 
myelinating phenotype of SCs (27). EGR2 is also a marker of my-
elinating SCs that is downregulated in the repair phenotype and 
upregulated in the re-myelinating phenotype of SCs (28). Next, 
we checked the effect of different concentration of FA supplemen-
tation on the phenotypic characteristics of SLCs. Compared with 
conventional SLCs, SLCs (FA) generated by our new protocol 
with adding 50 μg / ml FA in the step 3 displayed lower mRNA 
expression of both ERBB2 and EGR2 (P < 0.01, Mann-Whitney U 
test, Fig. 3).
New protocol enhances the mRNA expression and the secretion of 
NGF from SLCs
PCR analysis showed that SLCs (FA) generated using the 
new protocol had the highest level of NGF mRNA than that in 
ADSCs, primary SCs and other groups of SLCs (P < 0.01, one 
way-ANOVA, Fig. 4A). Furthermore, we collected supernatants 
from the above groups to compare NGF expression at the protein 
level. The new protocol significantly increased the NGF secretion 
capacity of SLCs (FA) compared with conventional SLCs (40.380 
± 0.803 pg / ml vs. 19.056 ± 0.580 pg / ml, P < 0.01, one way-ANO-
VA). In primary SCs, after stimulation with FA for 3 days, the 
NGF secretion also increased (12.461 ± 0.103 pg / ml vs. 49.115 ± 
1.854 pg / ml, P < 0.01, one way-ANOVA).
Table 1.　Summary of activators for promoting SC or SLC functions
Activator Functions of SCs or SLCs Feasible Ref.
Folic acid (100 μg / ml)
▪ promotes proliferation 
▪ promotes migration
▪ promotes NGF secretion
▪ promotes NT3 / NT4 / 5 secretion
High Kim GB, 
et al. (13) 
Kang WB, et al. (18)
Carboxymethylated chitosan 
(200 μg / ml)
▪ promotes proliferation via the activation of Wnt / β-catenin 
signaling
▪ induces biosynthesis of NGF 
Moderate Tao HY, et al. (20)




▪ no effect on proliferation
▪ promotes SCs move from the proximal nerve segment and 
myelin sheath formation
Moderate Wang HK, et al. (22)
Melatonin (1 nM) ▪ promotes proliferation via ERK1 / 2 pathway Moderate Chang HM, et al. (23)
M2 receptor agonist,
Arecaidine Propargyl Ester 
(100 μM)
▪ increases NGF production and maturation
▪ decreases proliferation and migration 
▪ increases SC marker and myelinating marker expression 
▪ enhances changes in morphology
Side effect Piovesana R, et al. (24, 25)
Immunoglobulin
(20 mg / ml)
▪ reduces SC proliferation rates and accelerates growth of 
cellular protrusions
▪ stimulates SCs maturation.
▪ boosts myelin gene expression and myelination-related 
signaling pathways
▪ secretes IL-18 to promote axonal growth
Immunogenicity 
problemz Tzekova N, 
et al. (26) 
Abbreviation : nerve growth factor, NGF ; neurotrophin, NT ; extracellular signal-regulated kinase, ERK ; interleukin 18, IL-18
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Fig 2.　Morphological changes and expression of SC markers in SLCs (FA). (A) Microphotographs of H&E staining of ADSCs, SLCs (FA) 
and primary SCs (scale bar, 100 μm). (B) Relative mRNA expression of S100B (left) and p75NTR (right) in ADSCs, SLCs (FA) and primary 
SCs. (C) Confocal images showing the immunofluorescence staining for S100B and p75NTR in ADSCs, SLCs (FA) and primary SCs (scale 
bar, 200 μm). *P < 0.05 ; **P < 0.01, Mann-Whitney U test. adipose-derived stem cells, ADSCs ; Schwann cells, SCs ; Schwann-like cells, 
SLCs ; folic acid, FA ; S100 calcium-binding protein B, S100B ; p75 neurotrophin receptor, p75NTR.
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DISCUSSION
Many studies have reported using differentiated SLCs from 
various sources of stem cells to promote nerve regeneration 
(29-31). We focused on ADSCs, which exhibit several advantag-
es : 1) a sufficient number of ADSCs can be easily obtained from 
the patient’s own adipose tissue through a minimally invasive 
procedure ; 2) autologous ADSC transplantation poses fewer 
ethical issues and lower risk of tumorigenicity compared with 
the use of induced pluripotent or embryonic stem cells (32) ; and 
3) previous studies have shown excellent differentiation capabil-
ities of ADSCs, including differentiation into powerful IPCs and 
hepatocyte-like cells (8, 33). However, the protocols used in these 
studies are similar, and an improved protocol to obtain more 
useful SLCs requires further exploration.
This study used FA to induce stem cell differentiation. FA is 
a common water-soluble vitamin derivative. FA plays a key role 
in the growth, differentiation and regeneration of the CNS (34) 
and aids peripheral nerve repair via its neurotrophic effects. 
Yilmaz et al. have shown that FA protects diabetic rats from dia-
betic peripheral neuropathy by reducing malondialdehyde levels 
and upregulating NGF expression (35). Harma et al. have found 
that FA improved peripheral nerve healing and increased axon 
myelination in a rat sciatic nerve injury model (17). Bridging the 
Fig 3.　Relative expression of ErbB2 and EGR2 in different groups of SLCs. Relative mRNA expression of ERBB2 (A) and EGR2 
(B) in conventional SLCs, SLCs (FA, 10 μg / ml), SLCs (FA) and SLCs (FA, 200 μg / ml) groups. **P < 0.01, Mann-Whitney U 
test. adipose-derived stem cells, ADSCs ; Schwann-like cells, SLCs ; Erb-B2 receptor tyrosine kinase 2, ERBB2 ; early growth 
response 2, EGR2 ; folic acid, FA.
Fig 4.　Gene expression and secretion of NGF by ADSCs, SLCs and SCs. (A) Gene expression of NGF in ADSCs, different 
groups of SLCs and SCs. (B) NGF concentration in the supernatants of ADSCs, different groups of SLCs, SCs and SCs (50 
μg / ml) groups. **P < 0.01, one way-ANOVA. adipose-derived stem cells, ADSCs ; Schwann-like cells, SLCs ; SCs ; Schwann-like 
cells ; folic acid, FA ; nerve growth factor, NGF.
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sciatic nerve defect using an FA-coated nerve conduit improved 
the sciatic nerve function index and the nerve conduction veloc-
ity. Moreover, FA promoted proliferation, migration and NGF 
secretion by SCs (18). Our results showed that the new differ-
entiation cocktail induced a change in ASCD morphology into 
bipolar and tripolar spindle shapes along with the expression of 
typical SC markers, such as S100B and p75NTR, indicating effec-
tive differentiation into an SC phenotype.
After nerve injury, SCs transdifferentiate into so-called repair 
SCs, and promote lysis of myelin, attract macrophages to partic-
ipate in phagocytosis and secrete neurotrophic factors, such as 
NGF, to support and control neuronal function and guide axonal 
regeneration and axonal re-myelination (6, 28, 36, 37). Repair 
SCs are considerably different from immature SCs. Immature 
SCs fail to express mature SC markers, such as S100B and 
p75NTR. Studies have shown that ERBB2 may act as a matura-
tion signal to negatively regulate the growth of axons, allowing 
SCs to start re-myelination (38, 39). EGR2 is downregulated in 
repair SCs and upregulated during re-myelination (28, 40). In-
terestingly, different conditions used to induce SLC differentia-
tion determined the cell characteristics ; our new protocol seems 
to generate repair SLCs. Our results show that the dose of FA 
is related to the phenotypic characteristics of SLCs. Compared 
with 10 μg / ml and 200 μg / ml, the concentration of 50 μg / ml 
could decrease the gene expression of both ERBB2 and EGR2. 
There is little discussion in the literature on the state of the 
SLCs ; it is reasonable to infer that the repair phenotype of SLCs 
is the most beneficial for nerve regeneration when used to treat 
PNI. NGF may activate autophagy in SCs, accelerate removal 
and phagocytosis of myelin fragments, and promote regener-
ation of axons and myelin during the early stages of PNI (19). 
Some studies have added neurotrophic factors, such as NGF, 
into nerve conduits to improve the quality of nerve regeneration 
(41). Other studies have also changed the microenvironment 
of transplanted cells, e.g., using self-assembling hydrogels, to 
stimulate higher secretion of brain-derived neurotrophic factors 
and NGF (42). However, these approaches were limited by the 
short half-life and unstable properties of neurotrophic factors 
and by difficulties in preparing the graft. Therefore, there is an 
urgent need to find economical neurotrophic factors with long 
half-lives and gradual release. According to our results, adding 
FA into the differentiation protocol could promote the release of 
NGF by SLCs. However, the secretion of NGF by SLCs (FA, 200 
μg / ml) is not higher than SLCs (FA). We believe that due to the 
vulnerability of stem cells, excessive amount of FA might cause 
potential damage to SLCs. So, we set the concentration of FA as 
50 μg / ml in our new protocol. 
However, this study still has some shortcomings as theses 
SLCs (FA) generated by our modified protocol are still in con-
ventional two-dimensional pattern. Many researchers including 
our team (8, 9, 11, 43) have illustrated that the three-dimen-
sional (3D) cell culture pattern could promote the differentiation 
efficiency of stem cells and improve the final therapeutic effect 
of cell transplantation and cell therapy, which is considered to 
be the trend of tissue engineering and regeneration medicine. 
Therefore, we decide and have already begun to apply this new 
protocol combined with 3D culture technology for the generation 
of more powerful SLCs and explore its potential on the nerve 
regeneration in vivo and in vitro.
CONCLUSION
Our modified protocol effectively induced an SC phenotype in 
ADSCs both in morphology and expression of SC markers. Fur-
thermore, the addition of FA induced a repair phenotype typical 
of SLCs with decreased ERBB2 and EGR2 gene expression and 
enhanced NGF secretion. This new protocol improved the func-
tions of SLCs by using a stable and inexpensive vitamin and is 
promising for SC-mediated nerve regeneration. 
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